دانلود مقاله ISI انگلیسی شماره 31923
ترجمه فارسی عنوان مقاله

متابولیت فسفر مغزی و اختلالات متقاطع زمان آرام سازی در افراد وابسته به هروئین در شروع درمان نگهدارنده با متادون

عنوان انگلیسی
Cerebral phosphorus metabolite and transverse relaxation time abnormalities in heroin-dependent subjects at onset of methadone maintenance treatment
کد مقاله سال انتشار تعداد صفحات مقاله انگلیسی
31923 2015 10 صفحه PDF
منبع

Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)

Journal : Psychiatry Research: Neuroimaging, Volume 131, Issue 3, 15 September 2004, Pages 217–226

ترجمه کلمات کلیدی
31 - 2 هروئین - نگهدارنده با متادون - فسفولیپیدها
کلمات کلیدی انگلیسی
31P MRS; T2-RT; Heroin; Methadone maintenance; PCr; Phospholipids
پیش نمایش مقاله
پیش نمایش مقاله  متابولیت فسفر مغزی و اختلالات متقاطع زمان آرام سازی در افراد وابسته به هروئین در شروع درمان نگهدارنده با متادون

Cerebral bioenergetic and phospholipid abnormalities have been reported in heroin-dependent subjects. The goal of the present study was to characterize the neurochemical profile of subjects voluntarily enrolled in a methadone maintenance (MM) treatment program to overcome their heroin addiction. Participants included 43 heroin-dependent subjects during their first month of MM and 15 age-matched healthy individuals. Phosphorus magnetic resonance spectroscopy (31P MRS) and transverse relaxation times (T2-RT), which can reflect steady state cerebral perfusion and metabolism, were acquired at 1.5 T from an axial slice prescribed through the orbitofrontal and occipital cortices, including basal ganglia and frontal cortex. MM subjects exhibited reduced phosphocreatine (PCr) levels (−15.3%), elevated phosphodiesters (+ 12.9%, PDE) and significantly longer T2-RT ((+) 2.1%) compared with healthy comparison subjects. When MM subjects were stratified into subgroups based on treatment duration, we found a treatment duration effect on metabolite values but not T2-RT; reduced PCr was observed only after 8+ days of MM, and phosphomonoesters (PME) were elevated in the 15–28 day MM group. Taken together, these cross-sectional data suggest that the first month of MM treatment may be associated with altered cerebral bioenergetics and phospholipid metabolite levels.